Who are Clopidogrel and Ticagrelor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin and clopidogrel / Prasugrel, Chewing Ticagrelor LD, Blinded clopidogrel, OAC + clopicogrel, bivalirudin + clopidogrel + aspirin, prasugrel / clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clopidogrel-and-ticagrelor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Clopidogrel and Ticagrelor — Competitive Intelligence Brief

Clopidogrel and Ticagrelor (Clopidogrel and Ticagrelor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual P2Y12 receptor antagonist / Antiplatelet agent. Area: Cardiovascular.

phase 3 Dual P2Y12 receptor antagonist / Antiplatelet agent P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Clopidogrel and Ticagrelor (Clopidogrel and Ticagrelor) — University of Patras. This is a dual antiplatelet therapy combining two P2Y12 receptor antagonists that inhibit platelet aggregation through different binding mechanisms to reduce thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Clopidogrel and Ticagrelor TARGET	Clopidogrel and Ticagrelor	University of Patras	phase 3	Dual P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Aspirin and clopidogrel / Prasugrel	Aspirin and clopidogrel / Prasugrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy combination)	COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)
Chewing Ticagrelor LD	Chewing Ticagrelor LD	Sheba Medical Center	marketed	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
Blinded clopidogrel	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
prasugrel / clopidogrel	prasugrel / clopidogrel	Assistance Publique - Hôpitaux de Paris	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual P2Y12 receptor antagonist / Antiplatelet agent class)

University of Patras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopidogrel and Ticagrelor — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-and-ticagrelor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab